Treatment for Knee

Phase-Based Progress Estimates
Knee+2 More
All Sexes
What conditions do you have?

Study Summary

This trial will study the safety and effectiveness of a new type of artificial knee joint. The revision rate of the new artificial knee joint is expected to be less than 2.8% at 2 years postoperative.

Eligible Conditions
  • Knee
  • Arthroplasty
  • Replacement

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 2 year

2 year
Percentage of cases with revision of the Femoral Cone Augment or Tibial Cone Augment for aseptic loosening
Presence of end-of-stem pain in relation to the Triathlon Tritanium Cone Augments location.
Severity of end-of-stem pain.
Anderson Orthopaedic Research Institute (AORI) classification and Femoral Cone Augment size.
Anderson Orthopaedic Research Institute (AORI) classification and Tibial Asymmetric Cone Augment size.
Bone structure of tibia

Trial Safety

Trial Design

0 Treatment Group

145 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 year

Who is running the clinical trial?

Stryker OrthopaedicsLead Sponsor
59 Previous Clinical Trials
18,473 Total Patients Enrolled
2 Trials studying Knee
322 Patients Enrolled for Knee

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a candidate for revision of all femoral and tibial components of a total knee replacement.
You are willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 15th, 2021

Last Reviewed: October 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%